• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Virus Res . The influenza B virus candidate vaccine expressing H3 hemagglutinin developed in suspension MDCK cells confers protection against lethal

tetano

Editor, Senior Moderator
Virus Res


. 2026 Apr 2:367:199722.
doi: 10.1016/j.virusres.2026.199722. Online ahead of print.
The influenza B virus candidate vaccine expressing H3 hemagglutinin developed in suspension MDCK cells confers protection against lethal H3N2 avian influenza in BALB/c mice

Yushu Wu[SUP] 1 [/SUP], Weiyang Sun[SUP] 2 [/SUP], Yeting Xia[SUP] 3 [/SUP], Yue Feng[SUP] 4 [/SUP], Menglin Zhao[SUP] 5 [/SUP], Tiecheng Wang[SUP] 6 [/SUP], Xianzhu Xia[SUP] 7 [/SUP], Fang Yan[SUP] 8 [/SUP], Yuwei Gao[SUP] 9 [/SUP]


Affiliations
Free article Abstract

Influenza viruses cause annual seasonal epidemics and occasional pandemics. Vaccination is most effective at preventing influenza virus infections. Suspensions of the Madin-Darby canine kidney (MDCKs) cell line are used to manufacture cell-based influenza vaccines. In this study, we tested and optimized a range of culture conditions for a chimeric recombinant influenza virus rA/B-H3 in MDCK suspension cells, revealing that the optimal inoculation conditions were multiplicity of infection of 0.001, cell concentration of infection of 4.0 × 10[SUP]6[/SUP] cells/mL, addition of 2 μg/mL of L-1-tosylamide-2-phenylethyl chloromethyl ketone, time of harvest of 72 h. The optimal parameter setting in a 5-L bioreactor was 50 % dissolved oxygen and pH 7.2 ± 0.05. The rA/B-H3 has stability genetic after 15 passages in MDCKs. The rA/B-H3 had several immune responsesin mice. Hemagglutination inhibition (HAI) antibodies, micro-neutralizing (MN) antibodies, and IgG antibodies were induced in immunized mice, and the mucosal IgA antibody responses were detected in their lung lavage fluids. The IFN-γ-secretion and IL-4-secretion by the mouse splenocytes were induced after stimulation with the specific H3N2 HA protein. Immunized mice resisted the lethal challenge with a wild-type H3N2 influenza virus. This study demonstrated the reliability of the MDCK suspension cell platform for the production of the chimeric H3N2 candidate vaccine, and the rA/B-H3 candidate vaccine is a potentially safe efficial vaccine.

Keywords: BALB/c mice; Chimeric vaccine; Immunization; MDCK suspension cell; Process optimization.

 
Back
Top Bottom